Zacks Investment Research upgraded shares of Chiasma (NASDAQ:CHMA) from a hold rating to a buy rating in a research note issued to investors on Friday morning, Zacks.com reports. The brokerage currently has $5.50 price objective on the biotechnology company’s stock.
According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “
Other research analysts also recently issued reports about the company. ValuEngine downgraded Chiasma from a buy rating to a hold rating in a research note on Thursday, August 1st. Cantor Fitzgerald set a $18.00 price objective on Chiasma and gave the company a buy rating in a research note on Friday, June 28th. HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Chiasma in a research note on Tuesday, July 23rd. Piper Jaffray Companies assumed coverage on Chiasma in a research note on Wednesday, July 31st. They issued an overweight rating and a $11.00 price objective for the company. Finally, Brookline Capital Management reissued a buy rating on shares of Chiasma in a research note on Wednesday, July 24th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Chiasma has an average rating of Buy and a consensus target price of $12.30.
Shares of CHMA stock opened at $4.88 on Friday. The company has a market cap of $207.68 million, a price-to-earnings ratio of -3.81 and a beta of 1.18. The stock has a 50 day simple moving average of $6.19 and a 200-day simple moving average of $5.91. Chiasma has a 1-year low of $1.66 and a 1-year high of $9.25.
Chiasma (NASDAQ:CHMA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. On average, research analysts forecast that Chiasma will post -1.09 EPS for the current year.
In related news, Director Roni Mamluk sold 10,000 shares of the stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $6.35, for a total value of $63,500.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $63,500. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.30% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of CHMA. Millennium Management LLC purchased a new stake in Chiasma in the 4th quarter valued at $41,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Chiasma during the 2nd quarter worth $100,000. Cubist Systematic Strategies LLC grew its holdings in shares of Chiasma by 35.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 14,235 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 3,722 shares during the period. Citadel Advisors LLC purchased a new position in shares of Chiasma during the 2nd quarter worth $145,000. Finally, Invesco Ltd. purchased a new position in shares of Chiasma during the 2nd quarter worth $186,000. Institutional investors own 63.18% of the company’s stock.
Chiasma Company Profile
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Featured Story: Why is Cost of Capital Important?
Get a free copy of the Zacks research report on Chiasma (CHMA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.